Current status of development of oligonucleotide therapeutics

DOI Web Site Web Site 12 References

Bibliographic Information

Other Title
  • 核酸医薬開発の現状と今後の展望
  • カクサン イヤク カイハツ ノ ゲンジョウ ト コンゴ ノ テンボウ

Search this article

Abstract

Oligonucleotide therapeutics are single- or double-stranded DNA or RNA-based molecules consisting of short strand of nucleotides (generally 10-50 nucleotides). They are manufactured by chemical synthesis and act directly on RNA or protein. In recent years, oligonucleotide therapeutics, such as antisense oligonucleotides (ASOs), siRNAs, miRNAs, aptamers or CpG-motif oligodeoxynucleotides (CpG ODN), are active areas of drug development designed to treat a variety of genetic and/or intractable diseases. So far, eight oligonucleotide therapeutics have achieved marketing authorization in USA or Europe, i.e. fomivirsen (Vitravene®), pegaptanib (Macugen®), mipomersen (Kynamro®), eteplirsen (Exondys 51®), nusinersen (Spinraza®), inotersen (Tegsedi®), patisiran (Onpattro®), and hepatitis B vaccine containing CpG ODN (CpG1018) as adjuvants (HEPLISAV-B®), and more than 150 oligonucleotide therapeutics are currently in clinical development. In this review, I outline classification, modifications and mechanism of actions of oligonucleotide therapeutics, and introduce the current status of development of RNA-targeted oligonucleotide therapeutics (ASOs, siRNAs and miRNAs).

Journal

  • Drug Delivery System

    Drug Delivery System 34 (2), 86-98, 2019-03-25

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

References(12)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top